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ABSTRACT
An adult male patient presented with right eye (RE) 
proptosis. After history and investigations a working 
diagnosis of orbital pseudotumour was made. The 
patient presented without any identifiable risk 
factors of mucormycosis. Biopsy results confirmed 
the diagnosis of mucormycosis.
CASE SCENARIO:
A 39 year old man presented to the University 
Teaching Hospital (UTH) eye clinic with complaints 
of right sided headache, poor vision right eye (RE) 
for 2 months, tearing RE, numbness right brow and 
right side of face for 1 month. Left eye (LE) was fine 
and patient had no complaints concerning it.
In the past medical history patient had been seen at a 
private hospital three days earlier and was started on 
30mg oral prednisolone of which patient noticed 
some improvement. Family History was 
unremarkable and drug history was as above.
Ocular examination showed Visual Acuity (VA), RE 
6/60 and LE 6/6, Near Vision RE 24                LE 5 
and Colour Vision was abnormal for RE. RE 
Proptosis measured by Hartel’s was RE 25mm and 
LE 18mm giving 7mm difference. The Extraocular 
motility was restricted laterally RE and there was 
Relative Afferent Pupillary Defect (RAPD) whereas 
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Provisional diagnosis of Orbital Pseudo-tumour RE 
was made. Full Blood Count and Erythrocyte 
Sedimentation Rate (ESR) were normal. 
The CT Scan performed reported a tumour 
measuring 35 x 23 mm in the retro-bulbar space and 
anterior temporal lobe. The tumour was displacing 
the optic nerve superiorly and encasing lateral and 
medial recti muscles. The conclusion reached was 
orbital pseudo-tumour RE with a differential 
diagnosis of lymphoma.  
The CT Scan film below shows the retro-bulbar 
tumour described in the report
Other investigations done were fasting Blood Sugar 
which was normal (5.1 mmol/L), retroviral test, 




The patient was put on high dose oral prednisolone 
starting with 80mg then tapered by 5mg on every 
third day until the drug was  stopped. 
Ptosis and ophthalmoplegia developed in both eyes.  
The optic nerve disc / head became pale as shown in 
the picture below. 
Neurosurgeon was urgently consulted and  noted the 
similar findings. Craniotomy, orbital roof 
 
decompression and biopsy  was done.   The biopsy 
  results revealed fungal elements isolated; with a 
conclusion of mucormycosis.
 
The patient was commenced on Amphotericin B, 50 
mg IV for 21 days then once per week for 6 weeks. 
Following this treatment the RE pain reduced, 
proptosis reduced but VA was still NPL. Follow up 
CT Scans showed a shrunk tumour, though sinuses 
were still involved. The patient is currently on 
fluconazole 200mg once per day for life. 
Patient also received carbamazepine in the retro-
bulbar space to reduce the pain of the RE. Repeat 
biopsy done at the University Teaching Hospital 
(UTH) by the Ear Nose and Throat (ENT) surgeons 
also revealed mucormycosis. 
DISCUSSION
Mucormycosis is the term used to describe fungal 
 1
infections caused by fungi in the order Mucorales,  
and Mucor, Rhizopus, Absidia, and Cunninghamella 
species are most frequently implicated. 
Mucormycosis is also known as Zygomycosis. 
Mucormycosis is caused by common fungi 
frequently found in the soil and in decaying 
vegetation. Most individuals are exposed to these 
fungi on a daily basis, but people with immune 
2disorders may be more susceptible to infection.
Conditions most commonly associated with 
mucormycosis include diabetes (usually poorly 
controlled diabetes), chronic steroid use, metabolic 
a c i d o s i s ,  o r g a n  t r a n s p l a n t a t i o n ,  
leukemia/lymphoma, treatment with deferoxamine, 
3and HIV/AIDS.  Mucormycosis frequently involves 
the sinuses, brain, or lungs as the sites of infection. 
While oral or cerebral Mucormycosis are the most 
common types of the disease, this infection can also 
manifest in the gastrointestinal tract, skin, and in 
4
other organ systems.  In rare cases, the maxilla may 
5
be affected by Mucormycosis.  
The rich vascularity of maxillofacial areas usually 
prevents fungal infections, although more prevalent 
fungi, such as those responsible for Mucormycosis, 
5 can often overcome this difficulty. Trauma and the 
use of contaminated medical supplies over wounds 
are associated with cutaneous mucormycosis. In 
addition, patients with burns and those who use 
intravenous drugs are at a higher risk. Some patients 
with mucormycosis have no identifiable risk 
factors. 
Manifestation of mucormycosis
There are several ways mucormycosis can manifest. 
One such manifestation is direct fungal invasion 
into the vascular network which results in 
thrombosis and death of surrounding tissue by loss 
6of blood supply.  If the disease involves the brain 
then one would present with one sided headache 
behind the eyes, facial pain, fevers, nasal stuffiness 
that progresses to black discharge, and acute 
7sinusitis along with swelling of the eye.  Affected 
skin may appear relatively normal during the 
earliest stages of infection. This skin quickly 
progresses to an erythmic (reddening, occasionally 
with oedema) stage, before eventually turning black 
7
due to necrosis.  
 
Rhinocerebral disease may manifest as unilateral, 
retro-orbital headache, facial pain, numbness, fever, 
and nasal stuffiness that progress to black discharge. 
4 Initially, mucormycosis may mimic sinusitis. Late 
symptoms that indicate invasion of the orbital 
nerves and vessels include diplopia and visual loss. 
These late symptoms indicate a poor prognosis and 
are usually followed by reduced consciousness. The 
clinical findings one may get would be: 
Orbital swelling and facial cellulitis are 
progressive. Black pus discharges from the 
necrotic palatine or nasal eschars. 
w










Proptos is ,  p tos is ,  chemosis ,  and 
ophthalmoplegias indicate retro-orbital 
extension. Cranial nerves V and VII are the 
most commonly affected. Loss of vision can 
occur with retinal artery thrombosis. 
A reduced conscious state denotes brain 
4involvement.
Our patient presented classically with rhinocerebral 
disease and had the symptoms and signs fitting with 
the same disease pattern. Its interesting to note that 
the patient presented with no risk factors at all.
Other forms of mucormycosis can occur depending 
of which part of the body is affected.
1. This would include lung (pulmonary) 
mucormycosis which could present with:




Most patients with pulmonary disease have 
malignancies and a history of neutropenia. Lung 
examination may reveal decreased breath sounds 
4
and riles.
2. Gastrointestinal (GI) mucormycosis usually 
affects severely malnourished individuals. This may 
manifest with:




3. Symptoms of kidney (renal) mucormycosis 
include:
  Fever 
  Flank (side) pain
4  Renal failure.  
4. Symptoms of skin (cutaneous) mucormycosis 
include a single painful hardened area of skin that 
4 may have a blackened center.
5. Central Nervous System (CNS) disease manifests 
as headache, decreasing consciousness, and focal 
neurologic symptoms. Patients with CNS 
involvement may have a history of open head 
5
trauma, drug use, or malignancy.
Mortality/Morbidity
Mucormycosis carries a very high mortality rate 
4
(60-95%).  Pulmonary and GI diseases carry an even 
higher mortality rate because these forms are 
typically diagnosed late in the disease course. 
Rhinocerebral disease causes significant morbidity 
in patients who survive because treatment usually 
requires extensive, and often disfiguring, facial 
6surgery.
Race




Sex is not likely to affect the occurrence of 
mucormycosis because the underlying conditions 
are the major predisposing factors. Reviews of cases 
from single institutions show an equal sex 
distribution. However, a recent review of all 
published cases of pulmonary mucormycosis 
performed by Lee et al (1999) showed a male-to-
3 
female ratio of 3:1
Age
Mucormycosis is found in patients of a wide age 
4
range.
EXAMS, TESTS AND DIAGNOSIS 
Mucormycosis should be suspected if symptoms 
appear in individuals with immune disorders such as 
diabetes, HIV/AIDS or those with weakened 
immune systems such as transplant recipients. 
Depending on where the symptoms are, CT scans or 
MRIs may be done. Evaluation by specialist is 
recommended as dictated by the part of the body 
suspected to be involvement. A tissue specimen 
must be taken and analyzed in order to make a 
definitive diagnosis of mucormycosis. As swabs of 
tissue or discharge are generally unreliable, the 
diagnosis of Mucormycosis tends to be established 
9
by a biopsy specimen of the involved tissue.
Medical Journal of Zambia, Volume 37 Number 4 (2010)
270
This photomicrograph reveals a mature sporangium 
of a Mucor species fungus, which can be responsible 
for Mucormycosis.
TREATMENT
Prompt amphotericin B (50mg once per day) therapy 
should be administered due to the rapid spread and 
4,8,10mortality rate of the disease.  Amphotericin B 
works by damaging the cell walls of the fungi and is 
administered for a further 4–6 weeks after initial 
therapy begins to ensure eradication of the infection. 
Posaconazole has been shown to be effective against 
Mucormycosis, perhaps more so than amphotericin 
B, but has not yet replaced it as the standard of 
8,10
care.
After administration of either amphotericin B or 
Posaconazole, surgical removal of the “fungus ball” 
may be indicated. The disease must be monitored 
4,8carefully for any signs of reemergence.  
Surgical therapy can be very drastic, and in some 
cases of Rhinocerebral disease removal of infected 
brain tissue may be required. In some cases surgery 
may be disfiguring because it may involve removal 
7of the palate, nasal cavity, or eye structures.  Surgery 
4may be extended to more than one operation.  It has 
been hypothesised that hyperbaric oxygen may be 
beneficial as an adjunctive therapy because higher 
oxygen pressure increases the ability of neutrophils 
6,10 to kill the organism.
Mucormycosis may be treated right away with 
surgery to remove all dead and infected tissue, along 
with intravenous (directly into a vein) antifungal 
therapy. Surgical removal of infected tissue may be 
disfiguring because it may involve removal of the 
palate, parts of the nose, or parts of the eye. Without 
his aggressive surgery, however, chances of survival 
are greatly decreased.
PROGNOSIS
In most cases, the prognosis of Mucormycosis is 
poor and has varied mortality rates depending on its 
form and severity. In the rhinocerebral form, the 
mortality rate is between 30% and 70%, whereas 
disseminated Mucormycosis presents with the 
highest mortality rate in an otherwise healthy 
6patient, with a mortality rate of up to 90%.  Patients 
8
with AIDS have a mortality rate of almost 100%.  
Possible complications of Mucormycosis include 
the partial loss of neurological function, blindness 
7
and clotting of brain or lung vessels.  Mucormycosis 
has an extremely high mortality rate even with 
aggressive surgical intervention. Death rates range 
from 25 - 90% depending on the body area involved 
and the individual’s underlying immune problems.
PREVENTION
Because the fungi that cause mucormycosis are 
widespread, the most appropriate preventive 
measures involve improved control of the 
underlying illnesses associated with mucormycosis.
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